PMC7354100_01
Case 1: Computed tomography shows a left inferior pulmonary nodule and multiple enlarged mediastinal lymph nodes (A) Before anlotinib treatment and (B) After anlotinib treatment was given for 6 weeks. Red arrows: metastatic lymph nodes. Yellow arrows: primary lung tumor.
OTT-13-6645-g0001.jpg
PMC7354100_01_OTT-13-6645-g0001.jpg
F0001
Then, she received anlotinib treatment (12mg, D1-D14, Q3W) and partial response (PR) was detected after 1 month of treatment (Figure 1).
PMC7354100_02
Case 2: Computed tomography shows the primary tumor in the right lower lung and metastases in the left and right upper lung. (A) Before anlotinib treatment and (B) After anlotinib treatment was given for 4 weeks.
OTT-13-6645-g0002.jpg
PMC7354100_02_OTT-13-6645-g0002.jpg
F0002
Therefore, treatment with anlotinib (12mg, D1-D14, Q3W) was administrated as a third-line treatment. The primary tumor, metastases, and pleural effusion were significantly shrunk with PS improvement after 1 month of anlotinib treatment (Figure 2).
PMC7354100_03
Case 3: Computed tomography shows a mass in the right upper lobe with right pleural effusion. (A) Before anlotinib treatment and (B) After anlotinib treatment was given for 1 week.
OTT-13-6645-g0003.jpg
PMC7354100_03_OTT-13-6645-g0003.jpg
F0003